Poster Presentations: Wednesday, October 26, 2011 |

Oral Bosentan in Patients With Congenital Heart Disease Related Pulmonary Hypertenion and PWP >15 mm Hg: Safety, Tolerability, Clincial, and Haemodynamic Impact FREE TO VIEW

Michele D'Alto, PhD; Emanuele Romeo, PhD; Paola Argiento, PhD; Anna Correra, MD; Berardo Sarubbi, PhD; Antonietta Caronna, MD; Giancarlo Scognamiglio, PhD; Maria Russo, MD; Raffaele Calabrò, MD
Author and Funding Information

Second University of Naples - Monaldi Hospital, Naples, Italy

Chest. 2011;140(4_MeetingAbstracts):746A. doi:10.1378/chest.1112497
Text Size: A A A
Published online


PURPOSE: Pulmonary arterial hypertension (PAH) associated with congenital heart disease (CHD) is included in group 1 of the pulmonary hypertension clinical classification. However, patients with Eisenmenger syndrome may rarely have pulmonary wedge pressure (PWP) >15 mmHg, that theoretically exclude the diagnosis of PAH and the use of specific therapy. Aim of this study was to evaluate safety, tolerability, clinical and haemodynamic impact of oral bosentan in patients with Eisenmenger syndrome and PWP>15 mmHg.

METHODS: Clinical status, liver enzymes, WHO functional class, resting oxygen saturations, 6-min walk test (6MWT) and haemodynamics were assessed at baseline and after six month of oral bosentan therapy in patients with Eisenmenger syndrome and PWP>15 mmHg.

RESULTS: At baseline right heart catheterization, 9/62 (14%) patients (3 male, age 48±13 y) with CHD-related PAH and Eisenmenger syndrome showed PWP>15 mmHg (18.0±1.7 mmHg, range 16-20 mmHg). Transpulmonary pressure gradient (TPG) was 46±22 mmHg. All 9 patients were in WHO functional class 3. Two patients had complete AV canal, 3 ventricular septal defect, 2 atrial septal defect and 2 single ventricle. All patients well tolerated oral bosentan at common doses. No major side effects were observed during the follow-up. After 6 months therapy was observed a significant improvement in WHO functional class (2.5±0.4 vs 3.0±0.0; p<0.005), distance travelled in the 6MWT (365±74 vs 304±109 m; p<0.05), pulmonary vascular resistances index (15±4 vs 21±9 WU.m2; p<0.01) and pulmonary cardiac index (3.9±1.7 vs 2.9±1.0 l/min/m2; p<0.005). In contrast, PWP (17.2±2.3 vs 18.0±1.7 mmHg; p=ns) and TPG (41±18 vs 46±22 mmHg; p=ns) did not significantly change. Finally, bosentan did not worsen oxygen saturation (83±6 vs 82±7%; p=ns).

CONCLUSIONS: Bosentan was safe and well tolerated in adults with Eisenmenger syndrome and PWP>15 mmHg during 6 months of treatment. Clinical status, exercise tolerance and pulmonary haemodynamics significantly improved without compromising peripheral oxygen saturation.

CLINICAL IMPLICATIONS: Patients with Eisenmenger syndrome may rarely have pulmonary wedge pressure (PWP) >15 mmHg, that theoretically exclude the diagnosis of PAH and the use of specific therapy. Nevertheless, oral bosentan can be safely used in Eisenmenger patients having PWP >15 and <20 mmHg.

DISCLOSURE: The following authors have nothing to disclose: Michele D'Alto, Emanuele Romeo, Paola Argiento, Anna Correra, Berardo Sarubbi, Antonietta Caronna, Giancarlo Scognamiglio, Maria Russo, Raffaele Calabrò

No Product/Research Disclosure Information

09:00 AM - 10:00 AM




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543